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Background: Multiple studies indicate that the matrix metalloproteinase-9
(MMP-9)-1562C>T gene polymorphism may be associated with an increased risk
of coronary artery disease (CAD) in the Chinese Han population. However, a clear
consensus has yet to be established.
Objective and methods: A meta-analysis of 5468 subjects from 10 separate studies
was performed to explore the possible relationship between theMMP-9-1562C>T gene
polymorphism and CAD within the Chinese Han population. Pooled odds ratio (ORs) for
the association and the corresponding 95% confidence intervals (CIs) were evaluated by
a random or fixed-effect model.
Results: Our analysis confirms the association between the MMP-9-1562C>T gene
polymorphism and an increased risk of CAD within the Chinese Han population under
allelic (OR: 1.60, 95% CI: 1.25–2.04, P = 0.0002), recessive (OR: 3.05, 95% CI:
1.67–5.56, P = 0.0003), dominant (OR: 2.23, 95% CI: 1.49–3.35, P = 0.0001),
homozygous (OR: 3.41, 95% CI: 1.87–6.23, P < 0.0001), heterozygous (OR: 2.03, 95%
CI: 1.40–2.93, P = 0.0002), and additive genetic models (OR: 1.78, 95% CI: 1.33–2.39,
P < 0.0001).
Conclusions: In the Chinese Han population, the MMP-9-1562C>T gene
polymorphism is correlated with an increased risk of CAD. Therefore, Han Chinese
carriers of the -1562T allele may be at an increased risk of CAD.
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INTRODUCTION
Coronary artery disease (CAD) is a chronic condition with both hereditary and environmental
factors. The increasing prevalence of unhealthy lifestyles in China (i.e., extended periods of sitting,
a more sedentary lifestyle, a high-fat diet), the general aging of the Chinese population, and the
increasing rates of hypertension and diabetes have damaged the quality of life of many Chinese
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people and sharply increased CAD-associated morbidity and
mortality (Li, 2007). However, recent advancements in molecular
biology have allowed researchers to better elucidate the
pathogenic mechanism of CAD.
Matrix metalloproteinases (MMPs), a large family of zinc-
dependent proteolytic enzymes that have special functions
in extracellular matrix (ECM) degradation have been a
particular rich area of research. MMPs play a role in
multiple pathophysiological processes such as ECM degradation,
inflammation response, tumor metastasis, and atherosclerosis
(Castro and Tanus-Santos, 2013). Enhanced MMP expression
and activity also play a pivotal role in early arteriosclerosis, plaque
rupture, myocardial infarction, and heart failure (Tanner et al.,
2011). MMP-9 (also known as gelatinase B) is one the most
extensively researched MMPs and exhibits enhanced expression
in atherosclerosis injury sites. It has been also found that there
were many gene sequence variations in MMP-9 gene, of which
the locus rs3918242 (-1562C>T) in the promoter region was the
most reported gene locus.
MMP-9 gene, located in 20q11.2–13.1, spans 7.7 kb and
contains 13 exons. MMP-9-1562C>T mutation occurs in a
substitution of cytosine (C) for thymine (T). This mutation may
increase MMP-9 gene expression and risk of CAD development
by reducing the binding affinity with transcription inhibition
proteins.
Although many studies on the association between MMP-9-
1562C>T gene polymorphism and CAD have been performed
in China, the composite of these studies fail to provide a
consensus. In 2005, Tang et al found that MMP-9-1562C>T
gene polymorphism was significantly associated with CAD in a
Zhejiang population and T allele increased the CAD risk (Tang
et al., 2005). In 2007, Chen et al also reported a similar result
in another Hunan population (Chen et al., 2007). In contrast,
Wu et al failed to find an association betweenMMP-9-1562C>T
gene polymorphism and CAD in a Beijing population in 2009
(Wu et al., 2009) and Zhi et al observed no significant effects for
MMP-9-1562C>T gene polymorphism on CAD risk in a Jiangsu
population (Zhi et al., 2010).
We performed the current meta-analysis with the hopes to
provide a valuable conclusion on the association betweenMMP-
9-1562C>T gene polymorphism and CAD in the Chinese Han
population.
MATERIALS AND METHODS
Publication Search and Inclusion Criteria
The Web of Science, PubMed, Embase, the China Biological
Medicine Database, and the China National Knowledge
Infrastructure electronic databases were searched using the
terms “matrix metalloproteinase-9,” “coronary artery disease,”
or “coronary heart disease,” and “polymorphism” in our initial
search. Retrieved studies were published between 2005 and 2010
with the last study updated on March 26, 2016.
To meet our inclusion criteria, studies had to (a) evaluate
the association between MMP-9-1562C>T gene polymorphism
and CAD in the Chinese Han population. (b) diagnose CAD
according to the clinical symptoms combined with examination
results (i.e., coronary arteriography, electrocardiogram, treadmill
exercise test, echocardiography, myocardial perfusion imaging by
Emission Computed Tomography, etc.) with a minimal stenosis
rate of the major coronary artery diameter of more than 50% (c)
be a case-control or cohort study published in an official journals
or as a postgraduate dissertation.
Data Extraction
Data was extracted according to a standardized protocol. Two
investigators searched for duplicates while a third served as
an arbiter to resolve possible disagreements. Duplicate papers,
those that violated the inclusion criteria, or those that provided
deficient data were removed. Identical data sets used in different
studies by the same authors were used once. Abstracted data
consisted of the following items: the first author’s name,
publication year, region, number of genotypes, genotyping
method, study design, age, gender, and total number of cases and
controls.
Statistical Analysis
The odds ratio (OR) and its corresponding to 95% confidence
interval (CI) were used to measure the association between
MMP-9-1562C>T gene polymorphism and CAD. The Chi-
square-based Q-test was adopted to measure the effects between-
studies heterogeneity (P < 0.05 level) (Cochran, 1968).Variation
due to heterogeneity was assessed by the inconsistency index
I2. If heterogeneity were present in the study, the random-
effects model would be used to assess the combined OR (the
DerSimonian and Lairdmethod) (DerSimonian and Laird, 1986).
Otherwise, the fixed-effects model would be used (the Mantel-
Haenszel method) (Mantel and Haenszel, 1959). The pooled OR
was determined by Z-test and significance was set at P < 0.05.
The Fisher’s exact test was used to evaluate the Hardy-
Weinberg equilibrium (HWE) (P < 0.05). Potential publication
bias was assessed by Egger′s linear regression test on the natural
log scale of the OR to detect funnel plot asymmetry (P < 0.05
level) (Egger et al., 1997). The statistical analysis was performed
by STATA 11.0 software (StataCorp, College Station, TX).
RESULTS
Studies and Populations
Ten of the nineteen retrieved papers fit the inclusion criteria.
Of the nine excluded studies, one was a duplicate, four were
reviews, and another four were irrelevant to our interests. No
study was excluded for deviation from HWE. The ten studies
compiled the data from 3168CAD patients and 2300 controls
(Table 1, Presentation 1 in Supplementary Material; Tang et al.,
2005; Meng et al., 2006; Chen et al., 2007; Wang et al.,
2007; Wu et al., 2009; Gao and Wang, 2010; Ma et al., 2010;
Yong and Shi, 2010; Zhang et al., 2010; Zhi et al., 2010) and
represented seven provinces (Shanxi, Xinjiang, Jiangsu, Zhejiang,
Hunan, Tianjin, and Beijing). All subjects were of Han ethnicity.
However, there were substantial differences in the size of the
total patient population between these studies. The Wu N study
alone contributed 1356 CAD patients and 689 controls for this
Frontiers in Physiology | www.frontiersin.org 2 June 2016 | Volume 7 | Article 212
Li et al. MMP-9 Gene-1562C>T Gene Polymorphism and CAD
TABLE 1 | Characteristics of the investigated studies of the association between the matrix metalloproteinase-9 gene -1562C>T polymorphism and
coronary artery disease in the Chinese population.
Author Year Region CAD Control Age (years old) Gender (female/male) Sample size
(CAD/control)
CC CT TT CC CT TT CAD Control CAD Control
Tang et al. 2005 Zhejiang 73 27 1 91 13 1 64.1± 10.7 62.3± 11.2 73/28 86/19 101/105
Meng et al. 2006 Tianjin 91 26 0 80 18 1 56.4± 7.7 54.3± 8.1 40/77 32/67 117/99
Chen et al. 2007 Hunan 63 25 2 58 11 1 59.2± 10.4 57.7± 10.2 57/33 44/26 90/70
Wang et al. 2007 Shanxi 46 17 1 66 18 0 63.08± 13.3 62.55± 9.2 43/21 52/32 64/84
Wu et al. 2009 Beijing 1078 263 15 545 143 1 58.39± 10.84* 60.42± 9.07 1162/194 589/100 1356/689
Gao and Wang 2010 Jiangsu 49 38 9 59 18 1 64.45± 9.88 62.74± 9.17 59/37 45/33 96/78
Ma et al. 2010 Xinjiang 266 84 12 348 67 4 56.7± 9.4 55.2± 10.1 249/113 292/127 362/419
Yong and Shi 2010 Zhejiang 97 30 1 92 14 0 64.0± 10.47 61.0± 11.22 74/54 65/41 128/106
Zhang et al. 2010 Shanxi 67 22 3 83 12 0 54.50± 6.4 52.30± 6.9 62/30 59/36 92/95
Zhi et al. 2010 Jiangsu 585 174 3 442 110 3 67.46± 9.61 69.90± 11.48 543/219 372/183 762/555
CAD, coronary artery disease.
Polymerase chain reaction-restriction fragment length polymorphism genotyping method and Case-control study design were adopted in the above studies.
Compared with control group, *P < 0.05.
TABLE 2 | Summary of meta-analysis of association of matrix metalloproteinase-9 gene -1562C>T polymorphism and coronary artery disease in the
Chinese population.
Genetic model Pooled OR (95% CI) P-value Literature number CAD size Control size Pheterogeneity (I
2%)
Allelic genetic model 1.60 (1.25–2.04) 0.0002* 10 3168 2300 0.002*(65.1%)
Subgroup 1: CT1<30 1.74 (1.28–2.36) 0.0004* 5 464 453 0.38(4.0%)
Subgroup 2: CT1≥30 1.52 (1.10–2.11) 0.01* 5 2704 1847 0.001*(78.3%)
Recessive genetic model 3.05 (1.67–5.56) 0.0003* 10 3168 2300 0.50(0%)
Dominant genetic model 2.23 (1.49–3.35) 0.0001* 10 3168 2300 < 0.00001*(83.5%)
Subgroup 1: CC0>90 1.73 (1.13–2.65) 0.01* 5 2709 1874 < 0.0001*(83.6%)
Subgroup 2: CC0<90 3.40 (1.41–8.21) 0.006* 5 459 426 0.0003*(80.9%)
Homo genetic model 3.41 (1.87–6.23) < 0.0001* 10 3168 2300 0.43(1.1%)
Hetero genetic model 2.03 (1.40–2.93) 0.0002* 10 3168 2300 < 0.00001*(80.3%)
Subgroup 1: T1<110 3.19 (1.95–5.21) < 0.00001* 5 443 432 0.12(45.5%)
Subgroup 2: T1>110 1.41 (1.00–2.01) 0.05* 5 2725 1868 0.003*(75.1%)
Additive genetic model 1.78 (1.33–2.39) < 0.0001* 10 3168 2300 < 0.0001*(75.9%)
Subgroup 1: CT1<30 1.89 (1.34–2.68) 0.0003* 5 464 453 0.26(23.7%)
Subgroup 2: CT1≥30 1.72 (1.14–2.57) 0.009* 5 2704 1847 < 0.0001*(85.8%)
*P < 0.05. CAD, coronary artery disease; CI, confidence interval; OR, odds ratio; CAD size, the total number of CAD cases; control size, the total number of control group; homo genetic
model, homozygous genetic model; hetero genetic model, heterozygous genetic model; CT1, CT sample size of CAD group; CC0, CC sample size of control group; T1, Total sample
size of CAD group.
meta-analysis. Differences in patient number may be factor in the
lack of consensus on this topic.
Combined Analyses
There was a significant association between MMP-9-1562C>T
gene polymorphism and CAD in the Chinese Han population
under allelic (OR: 1.60, 95% CI: 1.25–2.04, P = 0.0002), recessive
(OR: 3.05, 95% CI: 1.67–5.56, P = 0.0003), dominant (OR: 2.23,
95% CI: 1.49–3.35, P = 0.0001), homozygous (OR: 3.41, 95%
CI: 1.87–6.23, P < 0.0001), heterozygous (OR: 2.03, 95% CI:
1.40–2.93, P = 0.0002), and additive genetic models (OR: 1.78,
95% CI: 1.33–2.39, P < 0.0001). (Table 2, Figures 1–6).
There was also significant heterogeneity under the allelic
(P = 0.002, I2 = 65.1%), dominant (P < 0.00001, I2 = 83.5%),
heterozygous (P < 0.00001, I2 = 80.3%) and additive genetic
models (P < 0.0001, I2 = 75.9%). Subsequent meta-regressions
explored the source of this heterogeneity under their respective
genetic models.
Under the allelic genetic model, CC sample size of CAD
group (CC1, P = 0.006), CT sample size of CAD group (CT1,
P = 0.005), TT sample size of CAD group (TT1, P = 0.010),
CC sample size of control group (CC0, P = 0.023), total
sample size of control group (T0, P = 0.034), and weight (%)
(P= 0.030)were possible confounding factors that could partially
explain heterogeneity between studies.
Under the additive genetic model, CC1 (P= 0.013), CT1 (P=
0.012), and TT1 (P = 0.016) were the confounding factors. In
the allelic and additive genetic models, CT1 plays a central role
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FIGURE 1 | Forest plot of coronary artery disease associated with MMP-9-1562C>T gene polymorphism under an allelic genetic model stratified by
CT1 (distribution of T allelic frequency of MMP-9 gene).
FIGURE 2 | Forest plot of coronary artery disease associated with MMP-9-1562C>T gene polymorphism under a recessive genetic model (TT vs.
CC+CT).
in explaining the source of heterogeneity. According to CT1, the
whole population was separated into two subgroups. The studies
with CT1 < 30 were grouped into subgroup 1 and the residual
studies with CT1 ≥ 60 belonged to subgroup 2.
Stratified by CT1, a subgroup analysis under allelic and
additive genetic models found significant association between
MMP-9-1562C>T gene polymorphism and CAD in both
subgroups (allelic genetic model: subgroup 1: OR: 1.74, 95%
CI: 1.28–2.36, P = 0.0004; subgroup 2: OR: 1.52, 95%
CI: 1.10–2.11, P = 0.01) (additive genetic model: subgroup
1: OR: 1.89, 95% CI: 1.34–2.68, P = 0.0003; subgroup 2:
OR: 1.72, 95% CI: 1.14–2.57, P = 0.009). No significant
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FIGURE 3 | Forest plot of coronary artery disease associated with MMP-9-1562C>T gene polymorphism under a dominant genetic model stratified by
CC0 (CT+TT vs. CC).
FIGURE 4 | Forest plot of coronary artery disease associated with MMP-9-1562C>T gene polymorphism under a homozygous genetic model (TT vs.
CC).
heterogeneity was fond in subgroup 1 (allelic genetic model:
Pheterogeneity = 0.38, I
2 = 4.0%; additive genetic model:
Pheterogeneity = 0.26, I
2 = 23.7%), but significant heterogeneity
was detected in subgroup 2 (allelic genetic model: Pheterogeneity =
0.001, I2 = 78.3%; additive genetic model: Pheterogeneity < 0.0001,
I2 = 85.8%). This identifies CT1 as the primary confounding
factor under the allelic and additive genetic models (Tables 2–4;
Figures 1, 6).
Under the dominant genetic model, CC1 (P = 0.015), CT1
(P = 0.009), TT1 (P = 0.009), CC sample size of control group
(CC0, P = 0.001), CT sample size of control group (CT0, P =
0.001), TT sample size of control group (TT0, P = 0.012), and
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FIGURE 5 | Forest plot of coronary artery disease associated with MMP-9-1562C>T gene polymorphism under a heterozygous genetic model
stratified by T1 (CT vs. CC).
FIGURE 6 | Forest plot of coronary artery disease associated with MMP-9-1562C>T gene polymorphism under an additive genetic model stratified by
CT1 (Total T vs. Total C).
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TABLE 3 | The meta-regression results among 10 studies in the Chinese population under an allelic genetic model for matrix metalloproteinase-9 gene
-1562C>T gene polymorphism.
Coefficient Standard Error T-value P-value 95% confidence interval
CC sample size of CAD group −0.0081427 0.0011763 −6.92 0.006* −0.0118862∼−0.0043991
CT sample size of CAD group 0.0405205 0.0054126 7.49 0.005* 0.0232951∼0.0577458
TT sample size of CAD group 0.0561608 0.009485 5.92 0.010* 0.0259754∼0.0863462
CC sample size of control group 0.0423375 0.0098008 4.32 0.023* 0.0111471∼0.0735279
Total sample size of control group −0.0337639 0.0090819 −3.72 0.034* −0.0626665∼−0.0048613
Weight(%) −0.2944788 0.0755127 −3.90 0.030* −0.534794∼−0.0541637
Cons 2.19458 0.4613965 4.76 0.018* 0.7262105∼3.662949
*P < 0.05. Coefficient: regression coefficient. The regression coefficients are the estimated increase in the lnOR per unit increase in the covariates. Cons, constant item.
weight (P= 0.001) could partly explain the heterogeneity source.
In a subgroup analysis stratified by CC0, significant increased
CAD risk was observed in both subgroups (subgroup 1: OR: 1.73,
95% CI: 1.13–2.65, P = 0.01; subgroup 2: OR: 3.40, 95% CI:
1.41–8.21, P = 0.006). Although heterogeneity was still detected
in both subgroups, it was significantly reduced in subgroup 2
(Pheterogeneity = 0.0003, I
2 = 80.9%), suggesting that CC0 was the
main confounding factor (Tables 2, 5; Figure 3).
Under the heterozygous genetic model, CC1 (P= 0.006), total
sample size of CAD group (T1, P = 0.011), and CT0 (P = 0.004)
could partly explain the heterogeneity. In a subgroup analysis
stratified by T1, significant increase in CAD risk was detected in
both subgroups (subgroup 1: OR: 3.19, 95% CI: 1.95–5.21, P <
0.00001; subgroup 2: OR: 1.41, 95% CI: 1.00–2.01, P = 0.05).
No significant heterogeneity existed in subgroup 1 any longer
(Pheterogeneity = 0.12, I
2 = 45.5%), but significant heterogeneity
was still observed in subgroup 2 (Pheterogeneity < 0.0001, I
2 =
85.8%; Tables 2, 6; Figure 5).
Sensitivity Analysis
In the current meta-analysis, the sensitivity analysis was
performed. After the Wu et al. was removed from the current
meta-analysis, the association between MMP-9-1562C>T gene
polymorphism and CAD was further strengthened under the
allelic genetic model (OR: 1.72, 95% CI: 1.35–2.19, P = 1.3 ×
10−5, Pheterogeneity = 0.04, I
2 = 50.0%; Wu et al., 2009). Removal
of other studies respectively from the current studies did not
change the results from the original analysis. Hence, the Wu
et al study should be the high sensitivity study in the current
meta-analysis.
Bias Diagnostics
The publication bias of the studies was evaluated by funnel plot
and Egger’s test. There was no visual publication bias in the
funnel plot (Figure 7). No statistically significant difference was
detected in the Egger’s test, implying no publication bias existed
in the current meta-analysis under the recessive genetic model
(T = −0.73, P = 0.487).
DISCUSSION
In the present meta-analysis, we found a significant association
between MMP-9-1562C>T gene polymorphism and CAD in
the Chinese Han population under allelic (OR: 1.60), recessive
(OR: 3.05), dominant (OR: 2.23), homozygous (OR: 3.41),
heterozygous (OR: 2.03), and additive genetic models (OR: 1.78).
Hence, it has been concluded that in Chinese Han population, the
MMP-9-1562C>T gene polymorphism may be associated with
the increased CAD susceptibility among Han Chinese.
What contributed to the recent controversy over the
association between MMP-9-1562C>T gene polymorphism and
CAD? The meta-regression used to reveal the source of the
heterogeneity detected under allelic, dominant, heterozygous
and additive genetic models (Pheterogeneity < 0.05) suggests that
patient number may have been the confounding factor. In the
heterogeneity source analysis, CT1 was possibly indicated to be
the main heterogeneity source under allelic and additive genetic
models. Although the subgroup analysis stratified by CT1 showed
a significantly increased risk of CAD in both subgroups, only
one subgroup exhibited heterogeneity. Hence, CT1 was the main
confounding factor contributing to the heterogeneity under the
allelic and additive models. Similarly, T1 and CC0 were major
confounding factors under heterozygous and dominant models,
respectively. CT1, T1, CC0 may be better matched between the
CAD and control groups under these genetic models.
Sensitivity analysis showed that our meta-analysis was most
sensitive to the Wu et al study. Although the pooled analysis
result without Wu et al study was different from the original
result (Wu et al., 2009), they are still consistent in associating
the presence of the gene polymorphism with an increased risk
of CAD.
MMPs belong to a neutral protease family that contains
zinc ions. MMP-9 is the leading MMP expressed and secreted
by the vascular cell walls. It is also secreted by monocytes,
neutrophils, vascular smooth muscle cells (VSMCs), and
endothelial cells. The relative molecular weight of MMP-9
is 92KD. In its active form its molecular weight is 84KD.
MMP-9 can degrade extensive ECM substrates, including Type
IV collagen, which plays a key role in the revascularization,
inflammation response, and atherosclerosis progression.
Research has shown an increased MMP-9 expression level in
the atherosclerotic arteries of human and animals compared
to normal arteries. The MMP-9 degradation activity was
most located in the shoulder regions of plaque, the lipid core
margin, and micro-vessels formation regions. This suggests
that MMP-9 may be associated with the coronary artery
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TABLE 4 | The meta-regression results among 10 studies in the Chinese population under an additive genetic model for matrix metalloproteinase-9 gene
-1562C>T gene polymorphism.
Coefficient Standard Error T-value P-value 95% confidence interval
CC sample size of CAD group −0.0091723 0.0017378 −5.28 0.013* −0.0147029∼−0.0036417
CT sample size of CAD group 0.0470359 0.0085234 5.52 0.012* 0.0199107∼0.0741611
TT sample size of CAD group 0.0699275 0.0141987 4.92 0.016* 0.0247408∼0.1151142
CC sample size of control group 0.007531 0.0022575 3.34 0.045* 0.0003466∼0.0147153
CT sample size of control group −0.0376383 0.0137834 −2.73 0.072 −0.0815034∼0.0062267
Weight −0.4013957 0.139735 −2.87 0.064 −0.8460947∼0.0433033
Cons 3.40343 1.011299 3.37 0.044* 0.1850261∼6.621835
*P < 0.05. Coefficient: regression coefficient. The regression coefficients are the estimated increase in the lnOR per unit increase in the covariates. Cons, constant item.
TABLE 5 | The meta-regression results among 10 studies in the Chinese population under a dominant genetic model for matrix metalloproteinase-9 gene
-1562C>T gene polymorphism.
Coefficient Standard Error T-value P-value 95% confidence interval
Study Region −0.0108937 0.0011565 −9.42 0.067 −0.0255888∼0.0038014
CC sample size of CAD group −0.0018324 0.0000437 −41.90 0.015* −0.002388∼−0.0012768
CT sample size of CAD group 0.016394 0.0002299 71.31 0.009* 0.0134728∼0.0193151
TT sample size of CAD group −0.0231394 0.0003334 −69.40 0.009* −0.0273758∼−0.018903
CC sample size of control group 0.0214946 0.0000441 487.42 0.001* 0.0209343∼0.022055
CT sample size of control group −0.0753318 0.0001097 −686.43 0.001* −0.0767263∼−0.0739374
TT sample size of control group 0.0395787 0.0007278 54.38 0.012* 0.0303313∼0.0488261
Weight −0.7719044 0.0014531 −531.20 0.001* −0.7903681∼−0.7534408
Cons 7.286745 0.0136083 535.46 0.001* 7.113836∼7.459655
*P <0.05. Coefficient: regression coefficient. The regression coefficients are the estimated increase in the lnOR per unit increase in the covariates. Cons, constant item.
TABLE 6 | The meta-regression results among 10 studies in the Chinese population under a heterozygous genetic model for matrix metalloproteinase-9
gene -1562C>T gene polymorphism.
Coefficient Standard Error T-value P-value 95% confidence interval
CC sample size of CAD group −0.0710505 0.013625 −5.21 0.006* −0.1088794∼−0.0332215
Total sample size of CAD group 0.0614264 0.013634 4.51 0.011* 0.0235723∼0.0992805
CT sample size of control group −0.0498063 0.0082049 −6.07 0.004* −0.0725867∼−0.0270259
Cons 0.4150886 0.3419184 1.21 0.292 −0.534229∼1.364406
*P < 0.05. Coefficient: regression coefficient. The regression coefficients are the estimated increase in the lnOR per unit increase in the covariates. Cons, constant item.
plaque stability and myocardial infarction (Speidl et al.,
2011).
The animal experiments have discovered that the
atherosclerosis lesions and VSMCs intima migration in the
MMP-9 gene knock-out mice were remarkably decreased than
that in the wild-type mice (Ye, 2006). The clinical researches
have confirmed that the high MMP-9 expression level was
correlated with the premature CAD, unstability of the coronary
atherosclerosis plaque, the in-stent restenosis and arterial
aneurysm formation (Jones et al., 2006). The prospective
researches have shown that plasmaMMP-9 contents can serve as
the prediction indicator for the cardiovascular diseases mortality
(Blankenberg et al., 2003).
MM9 is regulated primarily at the transcriptional level.
The MMP-9-1562C>T gene polymorphism is located in
crucial regulatory elements, including the 9 bp sequence
GCGCAC/TGCC (−1567→−1559), a potential binding
site for transcription inhibition proteins (Zhang et al.,
1999). In 2002, Cho et al reported a change in bond
zone structure and a weakened binding capacity between
DNA and transcription inhibition protein, when the
MMP-9-1562C allele was replaced by -1562T allele (Cho
et al., 2002). This generates a high and low activity
promoter genotype (CT/TT and CC, respectively) with
increased transcription with the high activity promoter
genotypes.
Increased MMP-9 expression may contribute CAD
development through a number of pathways. It may promote
the VSMCs proliferation and migration, promote the injured
vascular remodeling, and/or promote the plaque rupture and
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FIGURE 7 | Funnel plot for studies of the association of coronary artery disease and MMP-9-1562C>T gene polymorphism under a recessive genetic
model (TT vs. CC+CT). The horizontal and vertical axis correspond to the OR and confidence limits. OR, odds ratio; SE, standard error.
lead to the thrombosis, resulting in the acute coronary syndrome
known as myocardial infarction (Galis et al., 2002).
Past meta-analyses on the association of MMP-9-1562C>T
gene polymorphism and CAD (Li et al., 2012, 2013; Niu and
Qi, 2012) show weaknesses in their method. Although the
distribution of genes differs between populations, these meta-
analyses mixed ethnic Han Chinese with other ethnicities.
The present meta-analysis, on the other hand, studies only
the Han Chinese population. In addition, their initial search
for manuscripts was not as comprehensive as that of the
current meta-analysis, making their work less objective and
credible.
However, this meta-analysis is not without limitations.
The large-scale studies present in the analysis were not
adequate to fully elucidate the complex relationship between
the MMP-9-1562C>T gene polymorphism and CAD. The CAD
susceptibility is also influenced by environmental factors, such
as smoking, diabetes, dyslipidaemia, air pollution, inflammation,
and psychological factors (Wang et al., 2012; Agüero et al., 2013;
Parruti et al., 2013; Wichmann et al., 2013). It is quite possible
that the MMP-9-1562C>T gene polymorphism interact with a
risk factor that was not within the scope of this study. There
are also many other MMP-9 gene polymorphisms as P574R,
R+279Q, and R668Q that influence theMMP-9 serum level (Zhi
et al., 2010).
In conclusion, the current meta-analysis indicates that the
MMP-9-1562T allele may increase the CAD risk among the
Chinese population. This result has the potential to guide the
therapy strategy for a CAD patient. Taking into account the
limitations mentioned above, it remains necessary for these
results to be verified by future studies.
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